Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

French Off-Label Law Draws Industry Call For EU Action

This article was originally published in The Pink Sheet Daily

Executive Summary

Recommended use of an off-label drug for cost-saving reasons circumvents EU drug authorization process, trade groups say in complaint filed with European Commission; Avastin for wet AMD is currently at issue.

You may also be interested in...



EU Review Proposals ‘Fail To Analyze’ Impact Of Reduced Exclusivity Periods

Plans for the overhaul of the EU’s medicines framework are missing key analysis on the effect of reductions in data and market protection on the pharmaceutical industry, despite an abundance of studies on how such incentives influence company decisions on whether to develop new products, say lawyers from Sidley.

EU Commission Again Delays Pharma Revision Proposals, Citing ‘Busy Agenda’

Two members of the European Parliament claim the latest delay to publication of the long-awaited legislative revision is the result of pressure from the pharmaceutical industry.

Australia To Seek Stakeholder Input On Terms Of HTA Review

The review of the health technology assessment system will look at the use of adaptable and flexible approaches to managing future health care technologies, early and equitable access for patients, as well as the possibility of international work-sharing initiatives and comparisons of purchasing practices.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS078895

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel